Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 10/20 | 0.41 |
| ▸ | DYRK1B | Q9Y463 | 4/20 | 0.41 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.41 |
| ▸ | AURKA | O14965 | 2/20 | 0.41 |
| ▸ | DAPK3 | O43293 | 2/20 | 0.41 |
| ▸ | JAK2 | O60674 | 2/20 | 0.41 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.41 |
| ▸ | PAK4 | O96013 | 2/20 | 0.41 |
| ▸ | ABL1 | P00519 | 2/20 | 0.41 |
| ▸ | RET | P07949 | 2/20 | 0.41 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.41 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.41 |
| ▸ | FLT1 | P17948 | 2/20 | 0.41 |
| ▸ | LTK | P29376 | 2/20 | 0.41 |
| ▸ | GRK5 | P34947 | 2/20 | 0.41 |
| ▸ | KDR | P35968 | 2/20 | 0.41 |
| ▸ | CSNK1A1 | P48729 | 2/20 | 0.41 |
| ▸ | CDK8 | P49336 | 2/20 | 0.41 |
| ▸ | CLK2 | P49760 | 2/20 | 0.41 |
| ▸ | CDK7 | P50613 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29453046 | 1.00 | PIM1 (0.41) | PIM1DYRK1BDYRK1AAURKADAPK3 | |
| SCHEMBL10276899 | 1.00 | PIM1 (0.41) | PIM1DYRK1BDYRK1AAURKADAPK3 | |
| SCHEMBL6111556 | 0.76 | XDH (0.31) | — | |
| SCHEMBL21250746 | 0.75 | CSNK2A2 (0.39) | PIM1DYRK1BDYRK1AAURKADAPK3 | |
| SCHEMBL1854409 | 0.73 | PIM1 (0.54) | PIM1CSNK2BCSNK2A1CDC7CSNK2A2 | |
| SCHEMBL5731388 | 0.73 | KDM4E (0.44) | AURKAKDRMAPT | |
| SCHEMBL1253533 | 0.69 | KDR (0.62) | PIM1DYRK1BDYRK1AAURKADAPK3 | |
| SCHEMBL18552580 | 0.68 | KDM4E (0.42) | PIM1DYRK1BDYRK1AAURKADAPK3 | |
| SCHEMBL10276401 | 0.66 | NOS1 (0.44) | MAPT | |
| SCHEMBL10473673 | 0.64 | IDO1 (0.45) | PIM1DYRK1BDYRK1AAURKADAPK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12551487-B2 | PI3K inhibitor for use in the therapy of b cell lymphoma | CONVALIFE (SHANGHAI) CO. LIMITED (CN) | 2026-02-17 | — | — | US | disclosed |
| US-12257254-B2 | Compositions comprising phosphoinositide 3-kinase inhibitors and a second antiproliferative agent | CONVALIFE (SHANGHAI) CO. LIMITED (CN) | 2025-03-25 | — | — | US | disclosed |
| CN-113786409-B | Compositions comprising phosphoinositide 3-kinase inhibitors and a second antiproliferative agent | 甫康（上海）健康科技有限责任公司 | 2024-04-02 | — | — | CN | disclosed |
| US-11779586-B2 | Compounds comprising tricyclic heterocyclic compounds | CONVALIFE (SHANGHAI) CO. LIMITED (CN) | 2023-10-10 | — | — | US | disclosed |
| US-11708378-B2 | Tricyclic heterocyclic compounds as phosphoinositide 3-kinase inhibitors | CONVALIFE (SHANGHAI) CO. LIMITED (CN) | 2023-07-25 | — | — | US | disclosed |
| US-20230066999-A1 | COMPOSITIONS COMPRISING PHOSPHOINOSITIDE 3-KINASE INHIBITORS AND A SECOND ANTIPROLIFERATIVE AGENT | KARUS THERAPEUTICS LIMITED (GB) | 2023-03-02 | — | — | US | disclosed |
| EP-3337460-B1 | COMPOSITIONS COMPRISING TRICYCLIC HETEROCYCLIC COMPOUNDS | CONVALIFE SHANGHAI CO LTD (CN) | 2023-02-15 | — | — | EP | disclosed |
| EP-3337477-B1 | COMPOSITIONS COMPRISING PHOSPHOINOSITIDE 3-KINASE INHIBITORS AND A SECOND ANTIPROLIFERATIVE AGENT | CONVALIFE SHANGHAI CO LTD (CN) | 2023-02-01 | — | — | EP | disclosed |
| US-20220273667-A1 | PI3K INHIBITOR FOR USE IN THE THERAPY OF B CELL LYMPHOMA | CONVALIFE (SHANGHAI) CO. LIMITED (CN) | 2022-09-01 | — | — | US | disclosed |
| EP-3993804-A1 | PI3K INHIBITOR FOR USE IN THE THERAPY OF B CELL LYMPHOMA | Karus Therapeutics Ltd (GB) | 2022-05-11 | — | — | EP | disclosed |
| US-11291669-B2 | Compositions comprising phosphoinositide 3-kinase inhibitors and a second antiproliferative agent | KARUS THERAPEUTICS LIMITED (GB) | 2022-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11708378-B2 | Tricyclic heterocyclic compounds as phosphoinositide 3-kinase inhibitors | PIK3CA, PIK3C2A, PIK3C2B | PIM1 908/4885DYRK1B 2926/4885DYRK1A 2705/4885 |
| US-11291669-B2 | Compositions comprising phosphoinositide 3-kinase inhibitors and a second antiproliferative agent | MCL1, MYC, XIAP | PIM1 23/4885DYRK1B 2493/4885DYRK1A 2615/4885 |
| US-20220273667-A1 | PI3K INHIBITOR FOR USE IN THE THERAPY OF B CELL LYMPHOMA | BCL6, PIK3R5, BCL9 | PIM1 279/4885DYRK1B 3106/4885DYRK1A 3209/4885 |
| US-12551487-B2 | PI3K inhibitor for use in the therapy of b cell lymphoma | BCL9, BCL6, MALT1 | PIM1 460/4885DYRK1B 805/4885DYRK1A 837/4885 |
| US-12257254-B2 | Compositions comprising phosphoinositide 3-kinase inhibitors and a second antiproliferative agent | MCL1, MYC, XIAP | PIM1 23/4885DYRK1B 2493/4885DYRK1A 2615/4885 |
| US-11779586-B2 | Compounds comprising tricyclic heterocyclic compounds | GRN, GLA, HTT | PIM1 3744/4885DYRK1B 4023/4885DYRK1A 4143/4885 |
| US-20230066999-A1 | COMPOSITIONS COMPRISING PHOSPHOINOSITIDE 3-KINASE INHIBITORS AND A SECOND ANTIPROLIFERATIVE AGENT | MCL1, MYC, XIAP | PIM1 23/4885DYRK1B 2493/4885DYRK1A 2615/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.